Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

Inclusion Criteria: * Male or female patients aged ≥30 years * Diagnosis of idiopathic PD of \>3 years' duration, defined by the UK Brain Bank criteria (with the exception of \>1 affected relative being allowed), without any other known or suspected cause of Parkinsonism * Hoehn \& Yahr stage up to 3 in the ON and 2 to 5 in the OFF state * Motor fluctuations not adequately controlled on medical treatment including levodopa which was judged by the treating physician to be optimal * Average of OFF time \> 3 hours/day based on screening and baseline diary entries with no day with \< 2 hours of OFF time recorded * Stable medication regimen, with a stable dose of levodopa administered in at least 4 intakes, for at least 28 days prior to baseline. All oral or transdermal antiparkinsonian drugs were permitted, with the exception of budipine. This regimen might include the use of levodopa/DDCI rescue medication, if this occurred up to 2 times a day, at doses of up to 200 mg levodopa/day * Patients must be able to differentiate between the ON and OFF state and between troublesome and non-troublesome dyskinesias * Male and female patients must be compliant with a highly effective contraceptive method (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) during the study and for the 12-month OLP, if sexually active * Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) or u…